Merck (MRK) received European Union approval for its long-acting antibody Enflonsia to protect infants from Respiratory Syncytial Virus, a market expected to exceed $4 billion by 2036.
"This approval is a critical step in addressing the substantial burden of RSV in infants across Europe," said Dr. Eliav Barr, Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories.
The approval is based on results from the MELODY and HARMONIE clinical trials. The MELODY trial showed a 74.5% reduction in medically attended lower respiratory tract infections from RSV, while the HARMONIE study demonstrated an 83.2% reduction in RSV-related hospitalizations. The company has not yet disclosed specific safety data from the trials.
The EU nod for Enflonsia positions Merck to compete directly with Sanofi and AstraZeneca's Beyfortus, which is also approved for a similar indication. This approval opens a significant new revenue stream for Merck, with the company's stock expected to react positively to the news.
RSV is a common and contagious virus that is a leading cause of hospitalizations in infants. According to Boston Children's Hospital, most children will be infected with RSV by the time they are two years old. The approval of Enflonsia provides a new option for passive immunization to help prevent severe disease in this vulnerable population.
The global market for RSV treatments is expanding rapidly. A report from Future Market Insights projects the market to reach $4.25 billion by 2036, driven by the introduction of new preventative therapies and increasing awareness of the disease's impact.
The approval strengthens Merck's pediatric portfolio and provides a major growth driver. Investors will be closely watching the initial sales figures in the upcoming quarters to gauge market uptake against established competitors.
This article is for informational purposes only and does not constitute investment advice.
